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The multistep process of metastasis is a major hallmark of cancer progression involving the cointeraction and coevolution
of the tumor and its microenvironment. In the tumor microenvironment, tumor cells and the surrounding stromal cells
aberrantly secrete matricellular proteins, which are a family of nonstructural proteins in the extracellular matrix (ECM) that exert
regulatory roles via a variety of molecular mechanisms. Matricellular proteins provide signals that support tumorigenic activities
characteristic of the metastastic cascade such as epithelial-to-mesenchymal (EMT) transition, angiogenesis, tumor cell motility,
proliferation, invasion, evasion from immune surveillance, and survival of anoikis. Herein, we review the current understanding
ofthefollowingmatricellularproteinsandhighlighttheirpivotalandmultifactedrolesinmetastaticprogression:angiopoietin-like
protein 4 (ANGPTL4), CCN family members cysteine-rich angiogenic inducer 61 (Cyr61/CCN1) and CCN6, osteopontin (OPN),
secretedproteinacidicandrichincysteine(SPARC),tenascinC(TNC),andthrombospondin-1and-2(TSP1,TSP2).Insightsinto
the signaling mechanisms resulting from the interaction of these matricellular proteins and their respective molecular partner(s),
as well as their subsequent contribution to tumor metastasis, are discussed. In addition, emerging evidences of their promising
potential as therapeutic options and/or targets in the treatment of cancer are also highlighted.
1.Introduction
Cancer research has generally focused on cell-autonomous
behavior and the molecular genetics of malignant cells.
Malignant tumors, however, are more than a mere mass
of proliferating cancer cells. Tumors are highly complex
structures comprising a plethora of cell types and oncogenic
secretory factors and are structurally supported by the extra-
cellular matrix (ECM). In addition, cancer cells modulate
various cellular functions and participate in heterotypic
interactions via secreted factors to aid in growth and
metastasis. These interactions usually set oﬀ ac a s c a d eo f
downstream molecular signaling events that determine the
outcome of a malignancy.
Tumor metastasis is a multistep process involving the
acquisition of malignant cell phenotypes that allow cancer
cells to leave the primary tumor site and form secondary
metastases via blood circulation (Figure 1). Each of these
steps involves the cointeraction and coevolution of the
tumor and its microenvironment and is in part aﬀected by
the heterotypic interactions between the cancer cells and
neighboring stromal cells [1]. The tumor microenvironment
consists of a myriad of cellular components, such as the
non-malignant stromal ﬁbroblasts, and endothelial cells,
and an ECM comprised of proteins with structural and
regulatory functions, including collagen, ﬁbronectin and
matricellular proteins [1, 2]. Matricellular proteins are a
group of structurally diverse, ECM-associated glycoproteins,
that are secreted by tumor and neighboring stromal cells in
the tumor microenvironment [3, 4]. They have regulatory
roles, such as the modulation of cell-cell and cell-matrix
interactions, but do not contribute signiﬁcantly to the struc-
ture of the ECM [4]. These proteins facilitate and contribute
to various aspects of cancer cell behavior and growth, such
as epithelial-mesenchymal transition (EMT), angiogenesis,
cell proliferation and survival, as well as motility and ECM
degradation (Figure 1)[ 2]. Numerous studies have shown
how their interactions with the various cellular components
initiate downstream signaling events that culminate in the
acquisition of various hallmarks of cancer (Figure 2)[ 5].
In this review, we focus on six diﬀerent matricellular
proteins-angiopoietin-like protein 4 (ANGPTL4), CCN2 Journal of Oncology
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Figure 1: Summarized the signaling mechanisms of various matricellular proteins contributing to cancer progression. ANGPTL4 binds to
both integrins and ECM to promote tumor survival, tumor invasion and modulate the availability of ECM. (a) ANGPTL4 interacting with
integrin activates Rac1 and NADPH oxidase, which generate high level of O2
￿−. This will further activating the Src machinery and stimulates
its downstream PI3K/PKB mediated survival pathway. (b) ANGPTL4 interacting with integrin also activates FAK-src-PAK1 signaling and
PKC/14-3-3 mediated pathway which modulate cell migration via integrin internalization. (c) ANGPTL4 binds speciﬁc matrix proteins
and delays their degradation by proteases. However, this association does not interfere with integrin-matrix protein recognition unlike
TNC. (d) TNC can compete with ﬁbronectin to bind integrin α5β1 coreceptor, syndecan-4, which blocks the activation of promigratory
FAK/RhoA/ROCK signaling pathway. (e) TNC can activate Wnt signaling by downregulating the soluble inhibitor DKK-1, thus resulted
in nuclear localization of β-catenin. Nuclear β-catenin interacts with TCF/LEF to promote the expression of genes contributing to tumor
formation, survival, and metastasis. OPN can interact with several (f) integrins and also (g) CD44 family of receptors. These complexes
are able to mediate tumor cell survival through PI3k/PKB pathway activation and motility for detachment or invasion of tumor cell
through the activation of AP-1-dependent gene expression via the MEK/Erk pathway. (h) Certain domains of TSP1 (such as NoC1) can
bind directly to integrins to activate signaling proteins such as Erk1/2 and paxillin which modulates tumor formation. (i) TSP1 binding
to CD36 activates Fyn and p38 MAPK pathway which is essential for the suppression of tumor growth. (j) TSP1 can also bind CD47, to
modulate sGC and cGMP-dependent protein kinase, thus inhibiting the NO signaling necessary for angiogenesis. (k) TSP-1 association
with CD47 or direct competitive binding of TSP1 to VEGF can inhibit VEGFR2 signaling. VEGFR2 activates the PI3K/PKB pathway which
leads to activation of eNOS/NO signaling. Simultaneously, VEGFR2 can also signal through PLCγ, which further increases AMPK-mediated
eNOS phosphorylation and NO production. eNOS/NO signaling regulate downstream targets that increase endothelial cell proliferation,
migration, survival, and permeability. (l) TSP1 can activate TGFβ/smad pathway to inhibit tumor cell proliferation and induce apoptosis.
(m) SPARC binds integrin, inducing ILK/FAK/PKB activation to increase cell migration. (n) Cyr61 can promote tumor cell proliferation
and survival through the activation of integrin mediated signaling pathway either by direct binding with integrin or integrin-syndecan4.
The downstream intracellular events may be mediated through the FAK/PI3K/PKB signaling pathway, resulting in either activation of the
NF-κB survival pathway or phosphorylation of GSK3β and nuclear translocation of β-catenin for cell proliferation. (o) Cyr61 allows protein
degradation of E-cadherin leading to β-catenin translocation.Journal of Oncology 3
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Figure 2:Schematic illustrationofcancer progressionfromprimarytumortometastasizingcancer andtheinvolvement ofvariousmatricel-
lular proteins in each process. Aberrant expression of matricellular proteins in tumors or in the surrounding stromal cells induces or inhibits
thefollowingtumorigenicandcancerprogressionevents.(a)Epithelial-to-mesenchymaltransitionallowsanormalepithelialcell,whichnor-
mally adheres to basement membrane, to undergo a series of cellular and biochemical changes (i.e., a switch from E-cadherin to N-cadherin
and increased vimentin expression) to adopt a mesenchymal phenotype. (b) Promotion of cell proliferation and survival in tumor cells lead
to uncontrolled tumor growth. (c) Secretion of matrix metalloproteinases by tumor cells and acquisition of tumor cell motility result in
basement membrane degradation and the increased invasiveness of the tumor cells. (d) Intravasation of invasive cancer cells through the
basal membrane and endothelial monolayer allows the cancer cells to invade into the circulation. (e) Diminished immune surveillance and
leukocyterecruitmentagainstthecirculatingcancercellspermitthecellstosurviveinthecirculation.(f)Matricellularproteinsalsopromote
resistance against anoikis and chemotherapy in order for the cancer cells to survive in the circulation. (g) Interactions of the matricellular
proteins secreted by cancer cells with the surface receptors on endothelial cells result in an intermediate cell adhesion that allows the cancer
cells to dock on the endothelial monolayer. (h) Adhered cancer cells subsequently undergo trans-endothelial migration through a process
calledextravasationtoinvadeadistantsite.(i)Establishmentofnewtumorsatthemetastaticsiteisdependentontheproliferationofinvaded
cancer cells; (j) Neovascularization within the tumor mass via angiogenesis is crucial for tumors to grow beyond a certain size. (+) and (−)
denote positive and negative eﬀects, respectively, imposed by the indicated matricellular proteins on the selected events. The disparate
functions of any given matricellular proteins are dependent on the cell-type context and the speciﬁc structural domains that are expressed.
family members cysteine-rich angiogenic inducer 61
(Cyr61/CCN1) and CCN6, osteopontin (OPN), secreted
protein acidic and rich in cysteine (SPARC), tenascin C
(TNC), and thrombospondin-1 and -2 (TSP1, TSP2)—
highlighting their roles in metastatic progression. Although
the growing family of matricellular proteins consists of other
members of the small integrin-binding ligand N-linked
glycoproteins (SIBLINGs), lipocalin, and galectins, among
others, their roles in cancer have not been extensively studied
and shall be reserved for future reviews [2]. As tumor
metastasis is a major hallmark of cancer progression and
usually indicates a poor prognosis for the patient, this review
discusses the role and contribution of these six matricellular
proteins in the various steps of the metastatic process.
Furthermore, this review will discuss the signaling pathways
triggered by the interaction of these matricellular proteins
withtheirrespectivemolecularpartner(s)(Table 1)andtheir
subsequent contribution to tumorigenesis and metastasis
(Figure 1).
2. Epithelial-Mesenchymal Transition
Epithelial-Mesenchymal Transition is an important biolog-
ical process during embryonic development. During this
process, polarized epithelial cells, which are normally tightly
joined together through intercellular junctions and adhered4 Journal of Oncology
Table 1: Overview of the marticellular protein cell-adhesion signaling pathways and their biological and clinical implications.
Matricellular protein Cell adhesion partner(s) Signaling pathways Cellular and biological eﬀects Clinical implications
ANGPTL4 Vitronectin, Fibronectin,
Integrin β1, β5
TGFβ via smad signaling,
redox-based pro-survival via
PI3K/PKB and ERK1/2
downstream survival pathways
Regulates ECM availability, cell
migration, angiogenesis confers
anoikis eﬀect on tumor cells
Wound repair, cancer
metastasis
Cyr61
Integrin α2β1, α6β1, αDβ2,
αMβ2, αIIbβ3, αvβ3, αvβ5
Syndecan-4, perclean
PI3K/PKB, ERK1/2, MAPK,
NF-κB signaling pathways
Promotes cell proliferation,
motility, survival, invasiveness
confers anti-apoptotic
phentotype
Cancer metastasis and
tumorigenesis
OPN CD44, integrin αvβ1, αvβ3,
and αvβ5
NF-κB,VEGF signaling,
Src-mediated “inside-out”
signaling, integrin-linked ILK,
and PKB survival pathway
Integrin-mediated cancer cell
migration, angiogenesis,
inhibition of apoptosis ECM
degradation via MMPs
Cancer metastasis
SPARC Integrin α5β1 PKB prosurvival pathway Cancer metastasis
TNC Fibronectin, syndecan-4
MAPK, Wnt, TGFβ,E G F R ,
HGF, c-Met signaling
pathways
Induction of TNC expression,
cell proliferation, migration,
invasion Downregulation of
DKK-1, increased express and
nuclear accumulation of
β-catenin
Cancer metastasis
TSP1 Integrin α3β1, α4β1, α6β1,
αvβ3 CD 47, CD36
Fyn, capase-3, and p38
MAPK, inhibit eNOS/NO
signaling, inhibit
VEGF/VEGFR2 signaling
pathways
Inhibit endothelial cell migration
to reduce angiogenesis, modulate
level of sGC and
cGMP-dependent protein kinase
in endothelial cells
Inhibit metastasis via
its antiangiogenic
phenotype
to the basal membrane, undergo multiple biochemical
changes that enable the cells to acquire mesenchymal,
ﬁbroblast-like properties. EMT is characterized by the
disruption of cell-cell adherence mediated by E-cadherin,
the loss of apical-basal polarity, increased cell motility,
cytoskeleton reorganization and matrix remodeling through
the production of ECM components, such as ﬁbronectin
and type I collagen [6]. Several transcription factors have
been implicated in the repression of E-cadherin, including
zinc-ﬁnger proteins of the Snail (Snai1)/Slug (Snai2) family,
δEF1/ZEB1, SIP1, and the basic loop-helix E12/E47 factor
(see review [7]). Accumulating evidence has indicated the
occurrence of EMT-like events during tumor progression
andmalignanttransformation,therebyconferringtheincipi-
entcancercellswithinvasiveandmetastaticproperties[6,7].
In fact, a high-throughput study in melanoma identiﬁed
EMT as a major determinant of metastasis [8]. EMT is
now recognized as a potential mechanism for carcinoma
progression and a determinant of tumor staging. Several
matricellular proteins, such as SPARC, OPN, CCN1, CCN6,
and TNC, have been implicated in either the promotion
or suppression of EMT, highlighting their role in cancer
progression and malignant behavior of cancer cells.
SPARC, also known as osteonectin, is a secreted glyco-
protein and the prototypical member of a family grouped
on the basis of an extracellular calcium-binding module.
The ectopic expression of SPARC in normal melanocytes
induces a ﬁbroblast-like morphology characterized by
reduced epithelial markers on the transcript level (e.g., E-
cadherin and Mucin-1) with a concomitant increase in
mesenchymal markers, such as vimentin, ﬁbronectin, and
Lef-1 [9]. Moreover, these transfected cells exhibit a strong
reduction in P-cadherin expression, which was recently
found to promote cell-cell adhesion and counteract invasion
in human melanoma [9, 10]. The overexpression of SPARC
also stimulates melanoma cell invasiveness mediated by
the phosphorylation of focal adhesion kinase (FAK) and
Snail-induced repression of E-cadherin promoter activity
[11]. Integrin-linked kinase (ILK) interacts with integrin
subunitsβ1andβ3infocaladhesioncomplexesandhasbeen
known to be a key regulator of multiple signaling pathways
[11]. SPARC modulates ILK activity through direct protein-
protein interaction, which may be the mechanism responsi-
ble for the loss of E-cadherin and cell adhesion [12]. SPARC-
induced cell migration is likely to involve a mechanism
independent from the activation of the Arg-Gly-Asp (RGF)-
binding integrins αvβ3a n dαvβ5, as evidenced by the lack of
an RGD sequence in the SPARC protein [13]. These obser-
vations suggest that aberrant SPARC overexpression induces
EMT and the loss of intercellular adhesion, thus enhancing
cell migration, invasiveness and metastatic capacity.
Osteopontin (OPN) is a secreted transformation-associ-
ated phosphoprotein and has been implicated in tumorige-
nesis. The upregulation of OPN expression has also been
reported in a variety of human cancers, such as breast,
prostate, nonsmall cell lung cancer (NSCLC), and colon
carcinomas [14]. Importantly, several studies have suggested
a relationship between OPN levels and the progression of
these cancers [15–18]. Furthermore, the expression of OPN
is increased in NSCLC, and the overexpression of diﬀerent
OPN isoforms in NSCLC cell lines reveals functional het-
erogeneity associated with the individual isoform expressedJournal of Oncology 5
[19]. The ectopic expression of OPNa isoform results in
an increased expression of mesenchymal markers, including
MMP-2, MMP-9, Snail-1, Snail-2, N-cadherin, ILK, and
vimentin, with a concomitant downregulation of epithelial
markers, such as E-cadherin, desmoplakin, and cytokeratin
18 and 20 [19]. These data may partly explain the malignant
behavior of NSCLC cells as a result of EMT. Interestingly,
OPNa overexpression triggers EMT pathways and malignant
behavior in vitro, whereas OPNc overexpression results in a
decrease in the same properties. The only diﬀerence between
these isoforms is the transcription of exon 4, which is a 27
amino acid sequence at the N-terminus of the protein [19].
This suggests that exon 4 may act as an important regulator
of NSCLC malignant potential [19].
The CCN family of cysteine-rich matricellular proteins
contains six members in vertebrates [20]. CCN1 or Cyr61, in
particular, is known to play important roles in cell adhesion,
proliferation, migration, diﬀerentiation, and angiogenesis
during normal developmental and pathophysiological pro-
cesses [21]. An aberrant overexpression of Cyr61 has been
reported in various human cancers, including gliomas,
pancreatic ductal adenocarcinoma (PDAC), prostate, and
breast cancers [22–25]. Earlier reports also show that higher
levels of Cyr61 protein are associated with advanced breast
adenocarcinoma, PDAC, and gliomas, which suggest its
involvement in cancer progression and metastasis [22, 23,
25]. Cyr61 has been found to play a critical role in pancreatic
cancersandaggressivePDACcelllinesthroughtheinduction
of EMT and the expression of mesenchymal/stem cell
markers; additionally, stem cell-like Cyr61 silencing reduces
the aggressive behaviors of malignant cells by obliterating
the interlinking pathological events, such as EMT reversal,
blocking the expression of mesenchymal traits, and inhibit-
ing migration [23]. In contrast, CCN6 exhibited inhibitory
eﬀects on breast cancer growth and invasion. CCN6 protein
levels are reduced in invasive carcinomas T with lymph
node metastasis [26–28]. Notably, the downregulation of
CCN6 promotes EMT and invasion in nontumorigenic
breast epithelial cells by upregulating mesenchymal proteins
and decreasing epithelial proteins [27, 29]. The molecular
basis of CCN6-mediated EMT in mammary epithelium
likely involves the induction of Snail and ZEB1 transcription
levels and the subsequent inhibition of E-cadherin promoter
activity [27]. The administration of exogenous recombinant
CCN6 protein can impede the activation of the insulin-like
g r o w t hf a c t o r( I G F - ) 1p a t h w a ya n dl e a dt oar e d u c t i o ni n
ZEB1 expression, suggesting that the CCN6-mediated inhi-
bition of ZEB1 transcription is dependent on the attenuation
of the IGF-1 signaling pathway [27, 30].
Tenascin-C (TNC) was ﬁrst discovered as a protein in
the stroma of gliomas and as a myotendinous antigen in
connective tissues [31]. TNC is the founding member of
a group of secreted matricellular glycoproteins consisting
of the tenascins-X, -R, -Y, and -W [31]. The increased
expression of TNC in glioma, breast, and colon cancers
has been correlated with a poor survival prognosis [32,
33]. Recently, the expression of TNC was found to be
elevated in advanced melanomas and in the stem cell-like
side populations of the melanoma spheres, suggestive of
a role in cancer stem cells [34]. The administration of
exogenous TNC protein to the MCF-7 breast cancer cells
induces an EMT-like phenotypic change accompanied by
a delocalization of E-cadherin and β-catenin from cell-cell
contacts [35] .T h eE M Tp h e n o t y p ew a sa c c o m p a n i e db yt h e
activation of Src and FAK that are localized with αv integrin-
positive adhesion plaque, suggesting the involvement of
integrin αv-mediated pathways in TNC-mediated EMT [35].
Additional evidence demonstrated that treatment of breast
cancer cells with anti-αv integrin neutralizing antibodies,
and Src kinase inhibitors abrogates TNC-mediated EMT
[35].
There are four phases involved in the EMT process: the
proliferative phenotype of epithelial cells, the epithelial-to-
mesenchymal-like cell transition, the motility and migration
of the mesenchymal-like cell, and the reversion of EMT
through a process called the mesenchymal-to-epithelial
transition (MET). Matricellular proteins are likely to be
involved in all of these phases of EMT, thus identifying them
as novel therapeutic candidates for future drug development.
3. Cancer Cell Proliferation
Cancer cells exploit various signaling mechanisms to induce
autonomy in tumor growth through the development of
self-suﬃciency in growth signals, insensitivity to growth-
inhibitory (antigrowth) signals, the evasion of programmed
cell death (apoptosis), and a limitless replicative potential
sustained by angiogenesis, all of which contribute to the
uncontrolled proliferation in tumor cells. Stromal cells
of the tumor microenvironment play a dynamic role in
determining malignancy phenotype. Indeed, the prepon-
derance of evidence has implicated matricellular proteins
in the crosstalk between tumor and the surrounding stro-
mal ﬁbroblasts (CAFs) responsible for the acquisition of
properties that promote tumor development and metastasis
formation.
In contrast to the role of SPARC in promoting EMT,
SPARC expression in ovarian and pancreatic cancer cells
decreased tumor growth, increased apoptosis and reduced
the ability of cancer cells to induce tumors in nude mice [36–
38]. The decreased expression of SPARC in ovarian tumors
and pancreatic adenocarcinoma is attributed to the aberrant
hypermethylation of the SPARC promoter [37, 39, 40].
SPARC binds to several types of collagen, including collagen
I and III, which are the major structural proteins of the ECM
produced by host cells in response to the subcutaneously
injected tumor cells [40–42]. It was proposed that SPARC
exerts its anti-proliferative role in primary and metastatic
sites at least in part by increasing the collagen content and
mechanical stiﬀness of the ﬁbers surrounding the tumor,
thus restricting the growth of the tumor. However, the
role of SPARC in tumor development and metastasis varies
because of its context-speciﬁc functions (EMT promotion
versus inhibition of cell growth) [36]. The disparate eﬀect of
SPARCisalsoevidentbetweenstromalﬁbroblastsandcancer
cells. SPARC promotes the proliferation of stromal cells
while inhibiting cancer cells [43]. The apparent paradoxical
functionsof SPARCmay arise fromthediﬀerent biochemical6 Journal of Oncology
properties of the SPARC sources or from the diﬀerential
responses to SPARC from malignant and stromal cells.
In glioma cells, CCN1 can enhance tumorigenicity by
promoting cell proliferation and survival through integrin
αvβ3-andβ1-activatedILKstostimulatetheβ-cateninT-cell
factor (TCF)/lymphocyte-enhancing factor 1 (LEF-1) and
PI3K/PKB signaling pathways [22]. The elevated expression
of CCN1 in tumorigenic glioma cell lines accelerates their
growth in vitro and enhances their anchorage-independent
proliferation in soft agar [22]. The suppression of CCN1 by
antisense strategy abolishes anchorage-independent growth
[22]. The mechanism underlying this phenotype is likely
the phosphorylation of glycogen synthase kinase- (GSK-)
3β, followed by the subsequent cytoplasmic accumulation
and nuclear translocation of β-catenin leading to the tran-
scriptional activation of the promitogenic factor cyclin D1
[22]. Moreover, the overexpression of CCN1 also promotes
the PKB-mediated inhibition and phosphorylation of the
apoptotic eﬀector BAD to impede cell death induced by the
caspase cascades [22] .T h ep r o p r o l i f e r a t i v er o l eo fC C N 1i s
further substantiated by its ability to induce large and highly
vascularized tumors in nude mice [44]. CCN1 has been
shown to regulate breast cancer proliferation and survival
by participating in a positive CCN1-αvβ3 autocrine loop;
CCN1 stimulates the activation of ERK1/2-MAPK, which
increases the expression of integrin αvβ3 expression [44].
CCN1 has been identiﬁed as the direct target gene of cAMP-
response element-binding protein (CREB) in melanoma,
and its expression is negatively regulated by the CREB-
mediated inhibition of CCN1 promoter transcription [45].
TNC promotes cellular proliferation in a variety of cell
types, including tumor cells, carcinoma-associated ﬁbrob-
lasts and endothelial cells within the tumor stroma [32].
TNCharborsbothadhesiveandanti-adhesivesequencesthat
caneithersupportorpreventcellspreadingandproliferation
[32]. The interplay between TNC, endothelin receptor type
A (EDNRA), integrin α5β1, ﬁbronectin, syndecan-4, and
tropomyosin 1 has been reported to particularly contribute
toTNC-inducedcellproliferationincancerviatheactivation
of various signaling pathways (see [32]). For instance, TNC
was shown to stimulate cancer cell proliferation by inducing
EDNRA, the gene encoding the receptor for endothelin-
1, and by preventing cells from adhering to ﬁbronectin.
This eﬀect probably occurs through the competitive binding
of TNC to ﬁbronectin with the integrin α5β1c o r e c e p t o r ,
syndecan-4, which then blocks the activation of the RhoA
protein, FAK, and tropomyocin-1 in the process [46, 47].
Other signaling pathways activated by TNC that contribute
to enhanced cancer cell proliferation include the Wnt, TGF-
β and MAPK signaling pathways [32, 33, 48]. Furthermore,
tumor-derived TNC has been demonstrated to promote the
survival and outgrowth of pulmonary micrometastases by
enhancing the ﬁtness of metastasis-initiating cancer cells
through increased expression of stem cell signaling com-
ponents, such as leucine-rich repeat-containing G protein-
coupled receptor 5 (LGR5) and musashi homolog 1 (MSl1)
[49]. LGR5 is a target gene of the Wnt pathways, whereas
MSl1 is a positive regulator of Notch signaling [49]. These
signaling pathways have been implicated in cancer cell
proliferation and tumor formation [50, 51]. It is likely that
TNC increases the cell-autonomous expression of the Notch
and Wnt signaling components to promote the proliferation
of cancer cells in primary and metastatic tumors.
OPN has been implicated in tumor growth and metas-
tasis based on studies using gene expression analysis in
human and animal tumors, studies using DNA transfection
and clinical investigations in human malignancies [52–54].
In particular, higher levels of OPN expression have been
reported in three types of lung cancer, including small cell
carcinoma, squamous carcinoma, and adenocarcinoma [55].
The downregulation of OPN inhibits the proliferation rate
of a human lung adenocarcinoma epithelial cell line and in
vivo tumor growth by inducing G1-phase cell cycle arrest
and instigating late apoptosis and necrosis in these cells
[55]. Moreover, the proliferation and invasiveness induced
by OPN expression are linked to the diﬀerent OPN slice
variants;OPN-bmainlyaﬀectsthecellproliferation,whereas
OPN-c shows a strong correlation with invasive behavior
[55]. Collectively, OPN has been identiﬁed as a potential
biomarker for proliferation and invasiveness in lung cancer.
Angiopoietin-like 4 (ANGPTL4) was ﬁrst described as
an adipocytokine that participates in adipogenesis and as an
endocrine signal involved in the regulation of lipid and glu-
cose metabolism [56–58]. ANGPTL4 was recently deﬁned as
a matricellular protein with a potential role in tumor growth
[59, 60]; however, the role of ANGPTL4 in metastasis still
remains contradictory. Recently, prostaglandin E2 (PGE2)
and hypoxia were shown to have a synergistic eﬀect on the
expressionofANGPTL4incolorectalcancer[61].ANGPTL4
enhances colorectal carcinoma cell proliferation through
its eﬀects on STAT1 signaling mediated by the MAPK
and Src signaling pathways [61]. The clinical relevance of
these results is further validated by the ﬁndings that the
expressions of both ANGPTL4 and STAT1 are elevated in
half of the human colorectal cancers tested [61]. ANGPTL4
is also suggested as a diagnostic marker of primary and
metastatic sites in clear cell renal-cell carcinoma (ccRCC)
[62]. ANGPTL4 expression is widespread among various
tumors,anditssuppressionimpairstumorgrowthduetothe
enhanced apoptosis [63]. ANGPTL4 interacts with integrins
to stimulate the NADPH oxidase-dependent production of
superoxide, thereby triggering the PI3K/PKBα and ERK
p r o s u r v i v a lp a t h w a y sa sar e s u l to fh i g hs u p e r o x i d et o
hydrogen peroxide ratio and activated Src signaling [63].
4. Tumor Angiogenesis
Angiogenesis is an essential requirement for the metastatic
progression and growth of tumors. Apart from nourishing
tumors with nutrients and oxygen, the formation of new
blood vessels is also needed to aid the tumor cells in exiting
the primary tumor site and entering the blood circulation
for metastasis at a secondary site [64]. The vascularity of the
primary tumor correlates with the formation of metastatic
foci that will inherently aﬀect patient prognosis and survival
[64]. Tumor-induced angiogenesis is regulated by several
angiogenic factors, such as growth factors and adhesion
molecules [65–67]. Studies have also shown that ECM,Journal of Oncology 7
matricellular proteins, and stromal cells are involved in the
formation of tumor vasculature [65, 68–70]. The role of
some matricellular proteins in tumor angiogenesis remains
controversial, as there are various studies supporting both
pro- and antiangiogenic eﬀects.
T h eC C Nm e m b e r sw e r er e p o r t e dt ob ei n v o l v e di n
angiogenesis and tumorigenesis [21, 71, 72]. Earlier reports
showed that elevated levels of Cyr61 are associated with
advanced breast adenocarcinoma, PDAC, and gliomas,
which suggest its involvement in cancer metastasis [22,
23, 25, 73–75]. For instance, Cyr61-knockout mice develop
vascular defects that ultimately lead to embryonic death,
illustratingtheproangiogenicfunctionsofCyr61[76].Cyr61
alone can recapitulate angiogenic events in vitro by pro-
moting endothelial cell proliferation, adhesion, migration,
survival, and tubule formation through αvβ3 (activation-
dependent) and α6β1-heparin sulfate proteoglycan (acti-
vation independent) [77]. Moreover, ectopic expression of
Cyr61 in breast cancer-derived tumors induces increased
tumor growth and vascularization in vivo [25]. Although the
downstream intracellular events have yet to be ascertained,
the prosurvival eﬀect of Cyr61 on angiogenic endothelial
cells in breast cancer may be mediated through the integrin
αvβ3/focal adhesion kinase (FAK)/PI3K/PKB signaling path-
way [78].
OPN is a secreted matricellular phosphoprotein that
mediates angiogenesis by associating with integrin αvβ3o n
endothelial cells [79, 80]. Neovascularization was induced in
vivo by the constitutive overexpression of OPN in murine
neuroblastoma and breast cancer cells [81, 82]. OPN has
been postulated to upregulate the expression of Cyr61; both
OPN and Cyr61 may then interact with the integrin αvβ3
receptors on the surface of endothelial and tumor cells to
facilitate angiogenesis (see [83] ) .T h er o l eo fT N Ci nt u m o r
angiogenesis is unequivocal. Its expression has been corre-
lated with the degree of tumor neovascularization in human
gliomas and melanoma cells, and tumor cells xenografted
into TNC knockout mice demonstrate a regression of tumor
growth and angiogenesis [84, 85]. It has been postulated that
TNC promotes angiogenesis by acting as a chemoattractant
forendothelialcells,initiatingendothelialcelldiﬀerentiation,
survival, proliferation involving integrin αvβ3, and vascular
endothelial growth factor (VEGF) and also by stimulating
VEGFA expression, resulting in endothelial cell migration,
proliferation and the subsequent formation of capillaries in
the tumor [84, 86].
The thrombospondin (TSP)-1 and -2 family of matri-
cellular proteins are inhibitors of angiogenesis [87–89]. In
fact, their antiangiogenic function has incited interest as
them being anti-tumor agents [87]. TSP1 and TSP2 have
been demonstrated to suppress angiogenesis by inhibiting
endothelial cell migration, inducing endothelial cell apop-
tosis and preventing the interaction of growth factors with
the cell surface receptors of the endothelial cell [87–91].
Tumor cells with activated Ras can increase the level of myc
phosphorylation through the activation of the PI3K/Rho
pathway, which results in the inhibition of TSP1 gene
expression, creating an immediate pro-angiogenic tumor
microenvironment [92]. This pro-angiogenic eﬀect in the
tumor may also be partly regulated by the loss of the p53
tumor suppressor genes [93, 94]. Unlike the low expression
level of TSP1 in the tumor cell, adjacent stroma ﬁbroblast
cellscansecretehighlevelsofTSP1,suppressingangiogenesis
and tumor growth [95]. TSP1 can induce endothelial apop-
tosis and inhibit angiogenesis via the sequential activation of
CD36, Src family tyrosine-protein kinase (Fyn), caspase-3,
and the p38 MAPK cascade to curtail tumor growth [96, 97].
Conversely, a limited number of studies also showed an
angiogenic phenotype for these proteins. One study showed
that TSP1 induces a concentration-dependent outgrowth
of microvessels from rat aortic rings [87, 98]. Recently,
TSP1 was shown to induce neovascularization in quail
chorioallantoic membranes and in matrigel plug formation
assays via its interaction with integrin α9β1 on endothelial
cells [87, 99]. Although none of the studies point to a role
of TSP1 and TSP2 in tumor angiogenesis, such a postulation
cannot and should not be ruled out.
Similarly, SPARC possesses pro- and antiangiogenesis
phenotypes [36]. Although shown in limited studies as
pro-angiogenic, it is more often known as an antian-
giogenic agent and, thus, has sparked great enthusiasm
in its therapeutic potential for vascularized tumors [100–
104]. The overexpression of SPARC blocks angiogenesis
both in vitro and in vivo in neuroblastoma [105]. SPARC
overexpression also led to a signiﬁcant decline in microvessel
density, delayed tumor formation, and reduction of tumor
size in hepatocellular carcinoma xenografts [106]. SPARC
inhibits angiogenesis via a variety of molecular pathways,
such as interacting directly with angiogenic VEGF to pre-
vent interaction with its cognate receptor, thus preventing
endothelialcellproliferation.SPARCalsoindirectlyinhibited
angiogenesis by regulating angiogenesis-related genes, such
asmatrixmetalloproteases(MMPs)[107].Onatranslational
level, two antiangiogenic SPARC peptides have recently been
shown to inhibit the progression of neuroblastoma tumors
both in vitro and in vivo, heralding an optimistic future for
SPARC as an antivascular cancer therapeutic [108].
Recently identiﬁed as a tumor-secreted pro-metastasis
factor and as a matricellular protein, ANGPTL4 is upregu-
lated in many epithelial tumors [63, 109–111]. More impor-
tantly, it has been proposed to be a pro-angiogenic factor
that promotes neovascularization [112, 113]. ANGPTL4 was
shown to protect endothelial cells from apoptosis, promote
in vitro the tube formation of endothelial cells and promote
angiogenesis in an in vivo mouse model, suggesting a diverse
role for ANGPTL4 in metastasis [112, 113]. Although largely
acknowledged as a pro-angiogenic factor, a small number of
studies also portrayed ANGPTL4 as an antiangiogenic factor,
thereby preventing metastasis [114, 115]. The reason for
this discrepancy is still unclear; however, recent discussions
have suggested that the diﬀerence may be attributed to the
positionofthefusiontagintherecombinantANGPTL4used
in the various studies [116].
It is clear that angiogenesis is a “life-line” for tumors.
Without the formation of new vascular niches to pro-
vide continuous blood ﬂow and nutrients, most primary
tumors will not be able to grow beyond 1-2mm3 and/or
metastasize to secondary sites [117]. Given the myriad8 Journal of Oncology
molecularrolesthatmatricellularproteinsparticipateduring
tumor angiogenesis (or antiangiogenesis), these proteins
deﬁnitely warrant additional research to elucidate whether
they are pharmacological targets or agents. The addition
of matricellular proteins into the repertoire of antivascular
strategies will hopefully address some challenges in this
aspect of tumor biology and provide a viable alternative
treatment option for cancer and other vascular diseases.
5. Cancer Metastasis
The acquisition of migratory abilities in cancer cells is
a prerequisite for successful execution of the metastasis
process.Metastasisisamultipleprocess,beginningwithlocal
tumor invasion, followed by intravasation by cancer cells
into blood and lymphatic vessels, the transit of cancer cells
through the circulatory system, and the exiting of cancer
cells by extravasation into distant tissue for colonization
[118]. This migratory ability is often integrin-mediated
and is positively correlated with tumor metastasis [119–
121]. Integrins expressed on the surface of cancer cells are
important in all these processes, as they are needed for cell
adhesion via interaction with many ECM molecules includ-
ing ﬁbronection, other matrix proteins, and matricellular
proteins [119].
The role of TSP in cancer metastasis is complex; various
studies suggested a dual role of TSP1 acting as an adhesive
protein and a modulator of extracellular proteases to pro-
motetumorinvasion(seereview[122]).Theexpressionlevel
of TSP1 in metastatic cells is lower than in non-metastatic
or normal cells [123–125]. Notably, cancer patients with
low TSP1 expression have increased recurrence and lower
survival rates [126]. Breast carcinoma cells lacking the
adhesive motif on TSP1 displayed a suppressive eﬀect
on tumorigenesis [127]. The cell surface receptor CD47
binds to the adhesive motif Val-Val-Met on the C-terminal
domain of TSP1 [128]. The elevated expression of CD47
can stimulate β1 integrin-mediated cancer cell motility
via the inhibition of ERK activity and the suppression of
cyclic AMP levels [96, 129]. During metastasis, cancer cells
reduce their adhesion, detach from the primary tumor site
and invade the surrounding tissue through the cleavage
of ECM by proteolytic activity. Early studies demonstrated
that TSP1 upregulates plasmin, a proteolytic enzyme that
degrades ECM, thus aiding cell invasion [130]. At high
expression levels, TSP1 activates the plasminogen/plasmin
system and therefore promotes cell invasion; however,
reduced TSP1 expression levels promote the interaction
between cancer cells and matrix necessary for tumor growth
[130, 131].
Similarly, TNC also contains both adhesive and anti-
adhesive sequences that could either support or prevent cell
spreading [32]. TNC accumulates at the invasive front of
TNC-secreting cells, such as carcinoma cells and cancer-
associated ﬁbroblasts (CAFs) [32, 95]. A mechanistic study
showed that TNC promotes colon carcinoma cell invasion
via the epidermal growth factor receptor (EGFR) and
hepatocyte growth factor (HGF) signaling pathways; TNC
secreted by CAFs activates EGFR and HGF [132]. HGF binds
to its cognate receptor c-Met and triggers Rac activation,
while EGFR signaling inhibits RhoA activation, consistent
with the phenotypical signaling pathways in migratory cells
[132]. TNC also induced cell migration via its interaction
with promigratory factors (lysophosphatidic acid/platelet
derieved growth factor) together with PI3K, RhoKinase
(ROCK), and MAPK/ERK kinase (MEK) pathways [133,
134].
The expression of SPARC is induced in tissues under-
going repair in response to cellular injury and in epithelia
with a high ECM turnover [135, 136]. SPARC expression
is associated with aggressive invasion and metastasis in
prostate cancer, glioma, and melanoma cells [136–140]. The
inhibition of SPARC expression diminishes tumorigenicity
and metastatic dissemination of these cancer cells [102, 141].
SPARC interacts with diﬀerent ECM components, including
collagens, laminin, ﬁbronectin, and vitronectin [135, 142,
143]. It functions as a counter-adhesive agent by inducing
cell rounding and disassembly of focal adhesion contacts
in normal endothelial cells, most likely by antagonizing the
integrin-ECM interaction [5]. SPARC also inﬂuences the
secretion and activation of several MMPs, including MMP-
1, -2, and -7, to promote cancer invasiveness [107, 144,
145]. The increase in migration generated in response to
SPARC was mediated through the activation of integrins
αvβ3a n dαvβ5[ 13]. However, the SPARC protein does not
contain a RGD sequence; thus, the SPARC-induced motility
of cancer cells likely involves an indirect mechanism [12].
There is ample evidence suggesting that SPARC regulates
integrin signaling and the ability of integrins to interact
with structural components of the ECM by inﬂuencing the
activation of ILK [12, 146, 147]. SPARC reduces the surface
localization and clustering of integrin subunits αv, β1, β3,
and β5[ 148]. Altogether, these ﬁndings reveal that SPARC
inﬂuences integrin clustering and activation as well as its
ability to interact with ECM components. It is likely that the
diverse eﬀects of SPARC on tumor invasiveness are elicited
by its ability to control the pleiotropic interactions and
functions of integrins.
The expression of Cyr61 is elevated in advanced breast
adenocarcinoma, pancreatic cancer, gastric cancer, osteo-
sarcoma, and gliomas, among others [22–25]. Cyr61
promotes cancer cell motility and invasiveness through
cyclooxygenase-2 (COX-2) upregulation via αvβ3/NF-κB-
dependent pathways [149]. In addition, Cyr61 also pro-
motes the upregulation of chemokine receptors CXCR1 and
CXCR2 through the integrin αvβ3/Src/PI3K/Akt pathway,
which is involved in the transendothelial migration of
gastric cancer cells [150]. Cyr61 released by cancer cells
in hypoxic conditions is proposed to induce the activation
of plasminogen activator inhibitor-1 (PAI-1); however, it
also improved the invasion ability of cancer cells [151].
It appears to be contradictory that PAI-1 is required for
invasion because elevated PAI-1 should reduce plasmin
generation from plasminogen. It was believed that tumor
invasion requires the cooperation between both proteolytic
and inhibitory activities, most likely to control and conﬁne
the areas of invasive growth. It has been suggested that the
role of PAI-1 may be merely to protect tumors from ongoingJournal of Oncology 9
urokinase-type plasminogen activator-mediated proteolysis
while invading the ECM [152].
ANGPTL4 is one of the most highly predictive genes
associated with breast cancer metastasis to the lung, and it
is highly upregulated in ccRCC and oral tongue squamous
cell carcinoma [109, 113, 153]. The elevated ANGPTL4
expression in many highly metastatic epithelial tumors
suggests that ANGPTL4 is a critical mediator of the transmi-
gration process [63, 109–111]. Recent studies demonstrated
that ANGPTL4 expression in hepatocellular carcinoma can
promote transendothelial migration via the upregulation
of vascular cell adhesion molecules-1 (VCAM-1)/integrins
β1 signaling [154]. Consistently, TGF-β, which upregulates
ANGPTL4 in breast tumor cells, caused enhanced vascular
leakiness and promoted the transendothelial migration of
breast tumor cells to the lung [155]. In addition, tumor-
secreted ANGPTL4 can disrupt the junction between adja-
cent endothelial cells by interacting with integrin α5β1
to activate the Rac/PAK signaling, followed by interaction
with VE-cadherin and claudin-5 [116]. This results in the
internalization and declustering of the tight and adherens
junction proteins on the endothelial cells, leading to the
disruption of the vascular barrier that is believed to allow
invasion by the cancer cells [116]. Furthermore, clinical
studies have correlated ANGPTL4 expression to venous
and lymphatic invasion in human gastric and colorectal
carcinoma, which further emphasizes the role of ANGPTL4
in tumor metastasis [110]. In addition, elevated ANGPTL4
was shown to increase cell migration via the interaction with
vitronectinandﬁbronectinintheECMaswellasintegrinsβ1
and β5 on the cell surface [59, 60]. The former interaction
regulates the availability of the local ECM, whereas the
latter activates the integrin-mediated intracellular signal-
ing necessary for tumor cell motility [59, 60]. Together
these studies implicate tumor-derived ANGPTL4 in cancer
metastasis via its eﬀect on endothelial integrity and cellular
migration. Given the multitude of evidence pointing to
a role for ANGPTL4 in tumorigenesis, elucidating other
molecular mechanisms necessary for cancer progression that
are induced by this protein is worthwhile.
Given the myriad ways in which these matricellular
proteins contribute to cancer metastasis, it is likely that
they act cooperatively with other matricellular proteins to
induce cancer cell invasion. Studies on the interactive role
among these matricellular proteins are limited and further
investigationisnecessarytodesignmolecularlytargetedanti-
metastatic therapy.
6.EvadeImmuneSurveillanceand
AnoikisResistance
Apoptosis is a determinant factor modulating metastasis
eﬃciency. As a barrier to metastases, cells normally undergo
apoptosis aftertheylose contactwith theextracellularmatrix
(ECM), a cell-death process termed anoikis [156, 157].
The ability to survive in the absence of normal matrix
components (anoikis resistance) represents a crucial proper-
ty of metastatic cells that permits malignant tumor cells
to survive at crucial steps in the metastasis pathway [157].
The acquisition of anoikis resistance is a prerequisite for
the initial step of metastatic dissemination that requires the
detachment of epithelial tumor cells from the ECM [157].
Anoikis resistance is also required for cancer cell survival
while traveling through the lymphatic and circulatory sys-
tems into the secondary tissue sites [157]. Circulating tumor
cells also devise immunosuppressive strategies to avoid
patrolling innate immune cells, such as natural killer cells,
macrophages,oradaptiveimmuneresponsesinvolvingBand
Tl y m p h o c y t e s[ 158]. These immunosuppressive strategies
would increase tumor tolerance against immune responses
and improve their survival capabilities. In recent years,
membersofmatricellularproteinswereshowntobeinvolved
in diﬀerent aspects of the inﬂammatory response and cancer
cell survival during tumor development; therefore, a better
understanding of the molecular mechanisms underlying
anoikis resistance and immunosuppressive strategies would
oﬀer novel anticancer treatments.
Metastatic tumors are characterized by the overproduc-
tion of several matricellular proteins that are believed to play
a key role in more advanced steps of tumor progression, such
as tumor induced angiogenesis, the inhibition of inﬁltrating
immune cells and the protection of disseminated tumor
cells in circulation [156, 158, 159]. An increase in SPARC
activity is associated with diminished immune surveillance
during tumorigenesis [160]. In particular, melanoma cells
with suppressed SPARC expression resulted in enhanced
polymorphonuclear leukocyte (PMN) recruitment, a ﬁrst-
line of defense in the immune surveillance against cancer,
and in increased antitumor cytotoxic activity against tumor
growth in vitro and in vivo [102, 160]. Furthermore, the in
vivo depletion of PMN was able to reverse tumorigenesis of
SPARC-deﬁcient melanoma cells, suggesting that SPARC can
inhibit the recruitment of PMN to the tumor environment
[161]. Recent works highlighted that SPARC may mediate
its action by integrin-dependent signaling. SPARC deﬁciency
can induce the production of ﬁbronectin [12]. Fibronectin
activates integrin via the ILK activity and triggers the
production of speciﬁc chemoattractants for PMN, such as
GRO, IL8, and leukotriene [12, 146, 162–164].
OPN is highly expressed in chronic inﬂammatory dis-
eases and possesses chemotactic activity for macrophages
and neutrophils [165–167]. Elevated OPN expression in
breast,myeloma,andprostatecancersisassociatedwithpoor
prognosis [168–170]. OPN is secreted by host stromal cells
and cancer cells; however, the role of OPN in metastasis
is dependent on the site of production. Host-derived OPN
(hdOPN) in the ECM is in an aggregated form. hdOPN
could be antimetastatic by acting as a macrophage chemoat-
tractant, resulting in the inhibition of tumor growth, and
survival[165].OPNproducedbyendothelialcellswasshown
to promote angiogenesis and therefore favor metastasis [83].
In contrast, tumor-derived OPN (tdOPN) is in a soluble
form and acts as an inhibitor of macrophage functions,
thus promoting the metastatic process by supporting the
growth, invasiveness and survival of tumor cells in the
circulation [171, 172]. Early work showed that tdOPN inhib-
ited macrophage cytotoxicity against tumors, promoting
tumor dissemination [173]. Interestingly, OPN secreted by10 Journal of Oncology
macrophagesinhibitedtumorgrowth[174,175].Thus,these
observations warrant further investigation to determine the
precise role of speciﬁc cell-type, derived OPN and the
contribution towards tumor progression.
TNC expression is increased in cancer and noncancerous
inﬂammatory diseases [32, 49]. Early studies on tumor biop-
sies showed an inverse correlation between a higher density
of macrophagic/microglial inﬁltrates and TNC expression in
a malignancy group of glioblastomas, suggesting that TNC
may play a crucial role in regulating the inﬁltration of the
monocyte lineage in human glioma [176]. Indeed, other
studies also showed increased expression of TNC correlates
with the recurrence of NSCLC, where it inhibits the eﬀector
functions of tumor-inﬁltrating lymphocytes [177]. The stro-
mal compartment of TNC null mice contained signiﬁcantly
more monocytes/macrophages than the tumor stroma of
wild-type mice, suggesting that TNC might promote tumor
growth while at the same time blocking the inﬂammatory
inﬁltrates [178]. Furthermore, TNC inhibited in vitro T-
lymphocyte activation by blocking integrin α5β1- and
α4β1-mediated cell adhesion to ﬁbronectin, similar to the
eﬀect of SPARC on PMN via integrin-dependent signaling
[179, 180].
Early studies demonstrated that TSP1 produced by
squamous epithelial cells and monocytes plays a role in
monocyte-mediated killing of cancer cells [181]. The over-
expression of TSP1 in melanoma cells enhanced macrophage
recruitment into xenograft tumors grown in immunodeﬁ-
cient mice and polarized macrophages to the M1 antitu-
morigenic phenotype [182]. Consistent with the recruitment
of macrophages, TSP1 null mice exhibited a reduction in
inﬂammatory responses with a decrease in macrophage
recruitment [183]. Furthermore, TSP1 can inhibit T cell
receptor signal transduction and induce anergy in activated
T cells via CD47 [184, 185]. More recently, TSP1 was
shown to possess the capacity to generate regulatory T cells
(TREG) from naive T cells through CD47 [186]. Metastatic
melanoma secreted TSP1 or blocking of CD47 attenuated
the induction of TREGs by melanoma while induced TREGs
were able to actively suppress the immune response [187].
Furthermore, TSP1 can activate latent TGF-β, and the
activation of this immunosuppressive cytokine induces more
TREGs in the tumor microenvironment [188]. Interestingly,
SPARC can inhibit the production of TSP1 in endothelial
cells; however, the eﬀects of SPARC on the expression of
TSP1 in tumor remain elusive.
Anoikis resistance is essential for the survival of
metastatic tumor cells. A recent study demonstrated that
ANGPTL4interactswithintegrinstostimulatearedox-based
prosurvival pathway that confers resistance against anoikis
[63]. ANGPTL4-activated integrins increase O2
− generation
and stimulate downstream PI3K/AKT and ERK1/2 survival
pathways to confer anoikis resistance [63]. Speciﬁc neu-
tralizing antibodies against ANGPTL4 that antagonize the
interactionbetweenANGPTL4andintegrinsresultinadose-
dependent reduction in the O2
− :H 2O2 ratio and increased
apoptotic cancer cells. ANGPTL4 deﬁciency in cancer cells
also abolished the tumorigenic abilities of these cells in
a t h y m i cn u d em i c e[ 63].
It is evident that metastatic tumor invasion to distal sites
can be impaired by modulating the ability of tumor cells
to evade immune surveillance or its survival from anoikis.
Therefore, it is tempting to speculate that targeting these
matricellularproteins(e.g.,SPARC,ANGPTL4,andhdOPN)
would either increase the inﬁltration of immune cells to
inhibit tumor growth or induce apoptosis by stripping oﬀ
their anoikis survival capabilities. Future work is eagerly
awaited to validate this speculation because this ﬁnding
might open interesting therapeutic perspectives even to
cancer patient diagnosed with metastatic disease.
7. Therapeutic Exploitation and Conclusion
Despite the multitude of studies implicating matricellular
proteins in the metastatic cascade, the challenge still exists
for researchers to decipher more matricellular protein-
interactingpartnersandthemolecularsignalingmechanisms
in the midst of numerous confounding factors that occur
during tumor metastasis (Table 1). Although the activation
of the PI3K/PKB, ERK1/2 MAPK, and NF-κB signaling
pathways by diverse matricellular proteins appears to be a
recurrent theme by which matricellular proteins modulate
tumor survival and growth, there is still much to elucidate
on how exactly these matricellular proteins modulate and
orchestrate the entire metastastic process. Nevertheless,
given their multifaceted roles in tumorigenesis, matricellular
proteins should be considered strong potential therapeutic
targets in cancer treatment (Figures 1 and 2). Indeed, several
clinical studies have already established the use of matricel-
lular proteins as prognostic markers for tumor progression
[72, 189, 190]. To date, various therapeutic approaches to
either increase or reduce the levels of matricellular proteins
are being developed for cancer treatment. These approaches
include cell-based gene therapy and the systemic delivery of
neutralizing antibodies, recombinant proteins, or synthetic
peptides.
In cell-based gene therapy, a recombinant adeno-
associated virus mediates the delivery of a vector expressing
either the matricellular protein of interest or selected mod-
ules of the matricellular protein involved in the cell adhesion
moleculeinteraction.Forinstance,thedeliveryofadenovirus
encodingthetypeIIIrepeatdomainofTSP1inhibitedprolif-
erationandinducedapoptosisofamelanomacelllineinvitro
and in vivo [191]. Blocking the integrin receptors by RGD
peptidomimeticagentsorthepeptidefragmentofCD44may
be used to interfere with their respective OPN interactions,
impairing tumor motility and survival [192, 193]. Addition-
ally, the ablation of SPARC transcription using antisense
RNAhassuccessfullyinhibitedhumanmelanomaandgastric
cancer growth in nude mice [102, 194]. Recently, two antian-
giogenicSPARCpeptideshaverecentlybeenshowntoinhibit
the progression of neuroblastoma tumors both in vitro and
in vivo, heralding an optimistic future for SPARC as an
antivascular cancer therapeutic [79]. The use of neutralizing
antibodies against target matricellular proteins expressed in
tumors could also be a viable therapeutic option. Recently,
the use of a monoclonal antibody against ANGPTL4 causedJournal of Oncology 11
a signiﬁcant retardation in the growth of melanoma in a
murine model via a redox-based apoptotic pathway [63].
Matricellular proteins reside at the crossroads of cell-
matrix communication and can serve as modulators for
regulatory networks of metastasis and tumorigenesis. Matri-
cellular proteins act to provide signals that inﬂuence cell
activities characteristic of the metastatic cascade, such as cell
proliferation, migration, survival, angiogenesis, EMT, and
the maintenance of specialized stem cell niches. Owing to
these properties, the manipulation of matricellular proteins
for the adjuctive or multimodal therapeutic anti-tumor
treatments may fare better in treating cancer than therapies
that target one event. Therefore, a more detailed under-
standing of matricellular proteins and their respective cell
adhesion signaling pathways is critical not only to advance
basic oncology knowledge but also for the design of new
anticancer therapeutic strategies.
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